Abbott Laboratories vs. Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
ABT
Abbott Laboratories
$107.81 -0.14%
VS KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$76.06 -0.59%
Abbott Laboratories and Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| ABT | KNSA | |
|---|---|---|
| Market Cap | $186.55 billion | $5.93 billion |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | — |
ABT leads on 1 of 1 size & scale factors.
Valuation
| ABT | KNSA | |
|---|---|---|
| P/E Ratio | 34.89 | — |
| Price / Book | 3.60 | — |
| Price / Sales | 4.00 | — |
ABT and KNSA split the valuation factors evenly.
Profitability
| ABT | KNSA | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | — |
ABT and KNSA split the profitability factors evenly.
Dividend
| ABT | KNSA | |
|---|---|---|
| Dividend Yield | 2.34% | — |
| Payout Ratio | 81.55 | — |
ABT and KNSA split the dividend factors evenly.
Risk & Sentiment
| ABT | KNSA | |
|---|---|---|
| Short Interest | 0.57% | 0.02% |
KNSA leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, KNSA overview, KNSA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.